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Background and aims
Source Data Verification (SDV) aims to assure data
quality and participant safety by checking trial data
against source data in site monitoring visits. SDV is
resource-intensive but its value is unclear. We evaluated
SDV in an ongoing phase III RCT of three prostate
cancer treatments (ProtecT) with no planned SDV.
Methods
Two experienced ProtecT Data Managers reviewed 20
randomly selected participants notes at 9 hospital visits
across the UK (around 7% participants per site). SDV
case report forms (CRFs) were completed using hospital
and trial records (blinded to original CRFs) including
baseline, eligibility, treatment and annual outcome
CRFs. CRFs were entered on a separate database. Staff
time, accommodation and travel costs were recorded
and analysed using university costing software.
Results
639 SDV CRFs were completed (mean 4/participant)
from 161 sets of available records (90% of those
requested) taking a mean of 51 minutes/participant.
Problems encountered included the knowledge required
to interpret medical records and interrogate computer
systems. SDV and original data were compared for con-
cordance, with errors categorised as critical/major/
minor. Trial CRFs were subsequently modified to
increase standardisation of data collection across sites.
Staff time was the major resource (£7,041) as was
£3,126 of subsistence/travel costs (total £10,167, £63/
participant, with overhead costs £17,480).
Conclusions
SDV was conducted at 9 site visits on around 5% of par-
ticipants in a cancer trial. Logistical issues hindered data
collection. Comparison of SDV data against trial data
helped improved trial CRFs. Further analysis will evalu-
ate data quality gains against the considerable costs.
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